BioCryst Pharmaceuticals Inc (NAS:BCRX)
$ 7.82 -0.37 (-4.52%) Market Cap: 1.62 Bil Enterprise Value: 2.18 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 75/100

BioCryst Pharmaceuticals Inc to Discuss APeX-2 Results Conference Call Transcript

May 21, 2019 / 12:30PM GMT
Release Date Price: $3.48 (-52.91%)
Operator

Good day, ladies and gentlemen, and welcome to the BioCryst Pharmaceuticals' conference call. (Operator Instructions) As a reminder, this conference call is being recorded.

I would now like to introduce your host for today's conference, Mr. John Bluth at BioCryst. Sir, please go ahead.

John D. Bluth
BioCryst Pharmaceuticals, Inc. - SVP of IR & Corporate Communications

Thanks, Lauren. Good morning, and welcome to our call to discuss the top line results from the APeX-2 trial. A press release and accompanying slides are available on our website.

Participating with me today are CEO, Jon Stonehouse; Chief Medical Officer, Dr. Bill Sheridan; CFO, Tom Staab; and Chief Commercial Officer, Lynne Powell. Following our remarks, we'll answer your questions.

Before we begin, I want to direct your attention to Slide 2, which discusses our use of forward-looking statements and potential risk factors regarding an investment in BioCryst. As detailed on the slide, today's conference call will contain forward-looking statements, including those

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot